FDA's Position on the Clozaril Patient Management System
Abstract
Carl C. Peck, M.D., director of the Center for Drug Evaluation and Research of the Food and Drug Administration, outlined FDA's position on clozapine's monitoring system in a letter to officials of the American Pharmaceutical Association in mid-March. The major portion of the letter is reprinted below.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
